Generated by AI
BioCardia, Inc. Common Stock represents an investment in BioCardia, a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. BioCardia’s current product portfolio centers on autologous and allogeneic cell therapy platforms, including CardiAMP and CardiALLO, which are designed to address unmet needs in heart failure and other serious cardiac conditions. The company also develops enabling medical technologies such as the Helix biotherapeutic delivery system and the Morph line of steerable guide and sheath products, which support precise delivery of therapeutic agents and procedures in cardiovascular care. BioCardia operates in the biotechnology and healthcare markets, where its work combines cell processing, targeted delivery, and regenerative therapy development for clinical use. Headquartered in Sunnyvale, California, BioCardia serves as a specialized participant in the broader field of advanced biologic and device-based cardiovascular treatment solutions.
Website320 Soquel Way
Sunnyvale, CA, 94085
United States
The latest articles about BCDA.
Summary of Nov 13's posts. Generated by AI.
Summary of Jun 5's posts. Generated by AI.
Summary of Jun 5's posts. Generated by AI.
Investors talking about BCDA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.